Table Of Contents
1. EXECUTIVE SUMMARY
2. DIABETES DISEASE OVERVIEW
2.1 WHAT IS DIABETES?
2.2 DIABETES DIAGNOSIS AND TREATMENT
2.2.1 Diagnosis
2.2.2 Treatment
2.3 DIABETES COMPLICATIONS
3. WHY IS THE DIABETES MARKET SO LUCRATIVE IN INDIA
3.1 INDIA HAS THE LARGEST DIABETIC POPULATION IN THE WORLD.
3.2 INDIA REPRESENTS ONE OF THE FASTEST GROWING MARKETS GLOBALLY
3.3 IMPROVING DIAGNOSIS AND TREATMENT RATES
3.4 LARGE UNTAPPED MARKET
3.5 BRIGHT OUTLOOK FOR INNOVATIVE DRUGS
4. THE INDIAN DIABETES EPIDEMIOLOGY
4.1 TOTAL PREVALENCE
4.1.1 Type1 & Type2 Prevalence
4.1.2 Urban and Rural Prevalence
4.1.3 Prevalence of Diabetes by Sex
4.1.4 Prevalence of Diabetes by Age Group
4.1.5 Prevalence of Diabetes in Various Regions in India
4.2 DIAGNOSIS AND TREATMENT RATES IN INDIA
5. THE INDIAN DIABETES MARKET
5.1 MARKET TREND (2005-2009)
5.2 MARKET SEGMENTATION (2005-2009)
5.3 MARKET FORECASTS (2010-2015)
6. THE INDIAN NON-INSULIN ANTI-DIABETICS MARKET
6.1 MARKET TREND (2005-2009)
6.2 COMPETITIVE LANDSCAPE (2005-2009)
6.3 MARKET FORECASTS (2010-2015)
6.4 MARKET SEGMENTATION (2005-2015)
6.4.1 Glitazones
6.4.1.1 Market Trend (2005-2009)
6.4.1.2 Competitive Landscape
6.4.1.2.1 Share of Key Players
6.4.1.2.2 Portfolio of Key Players
6.4.1.3 Market Forecasts (2010-2015)
6.4.2 Biguanides
6.4.2.1 Market Trend (2005-2009)
6.4.2.2 Competitive Landscape
6.4.2.2.1 Share of Key Players
6.4.2.2.2 Portfolio of Key Players
6.4.2.3 Market Forecasts (2010-2015)
6.4.3 Sulphonylureas
6.4.3.1 Market Trend (2005-2009)
6.4.3.2 Competitive Landscape
6.4.3.2.1 Share of Key Players
6.4.3.2.2 Portfolio of Key Players
6.4.3.3 Market Forecasts (2010-2015)
6.4.4 Alpha-Glycosidase Inhibitors
6.4.4.1 Market Trend (2005-2009)
6.4.4.2 Competitive Landscape
6.4.4.2.1 Share of Key Players
6.4.4.2.2 Portfolio of Key Players
6.4.4.3 Market Forecasts (2010-2015)
6.4.5 Dpp-IV Inhibitors
6.4.5.1 Market Trend (2008-2009)
6.4.5.2 Competitive Landscape
6.4.5.2.1 Share of Key Players
6.4.5.2.2 Portfolio of Key Players
6.4.5.3 Market Forecasts (2010-2015)
6.4.6 Glinides
6.4.6.1 Market Trend (2005-2009)
6.4.6.2 Competitive Landscape
6.4.6.2.1 Share of Key Players
6.4.6.2.2 Portfolio of Key Players
6.4.6.3 Market Forecasts (2010-2015)
6.4.7 Glp-1 Agonists
6.4.7.1 Market Trend (2008-2009)
6.4.7.2 Competitive Landscape
6.4.7.2.1 Share of Key Players
6.4.7.2.2 Portfolio of Key Players
6.4.7.3 Market Forecasts (2010-2015)
6.4.8 All other Classes
6.4.8.1 Market Trend (2005-2009)
6.4.8.2 Competitive Landscape
6.4.8.2.1 Share of Key Players
6.4.8.2.2 Portfolio of Key Players
6.4.8.3 Market Forecasts (2010-2015)
7. THE INDIAN INSULIN MARKET
7.1 MARKET TREND (2005-2009)
7.2 MARKET SEGMENTATION BY MOLECULE (2005-2009)
7.3 MARKET SEGMENTATION BY MODE OF ACTION
7.4 COMPETITIVE LANDSCAPE
7.4.1 Share of key Players
7.4.2 Portfolio of Key Players
7.5 MARKET FORECASTS (2010-2015)
8. ROAD BLOCKS
8.1 LOW AVERAGE PER PATIENT SPENDING ON DIABETES DRUGS
8.2 PREFERENCE FOR INEXPENSIVE AND OLDER DRUG CLASSES
8.3 HIGHLY FRAGMENTED AND ‘GENERICIZED’ MARKET
8.4 LOW RATES OF DRUG TREATED POPULATION IN RURAL AREAS
LIST OF FIGURES
Figure 2:1: The impact of Diabetes in the Human Body
Figure 2:2: Diabetes Complications
Figure 3:1: Global: Breakup of Patients by Region, (in %) 2010 & 2030
Figure 3:2: India: Tapped and Untapped Diabetes Market, (in Million US$), 2010
Figure 4:1: India: Total Number of Diabetes Patients* (in Million), 2005 & 2010
Figure 4:2: India: Total Number of Diabetes Patients* Forecast (in Million), 2010, 2015, 2020, 2025 & 2030
Figure 4:3: India: Total Number of Type1 Diabetes Patients* (in Million), 2005 & 2010
Figure 4:4: India: Total Number of Type-1 Diabetes Patients* (in Million), 2010, 2015, 2020, 2025 & 2030
Figure 4:5: India: Total Number of Type 2 Diabetes Patients* (in Million), 2005 & 2010
Figure 4:6: India: Total Number of Type-2 Diabetes Patients* (in Million), 2010, 2015, 2020, 2025 & 2030
Figure 4:7: India (Urban & Rural): Total Number of Diabetes Patients* (in Million), 2005 & 2010
Figure 4:8: India (Urban & Rural): Total Number of Diabetes Patients* Forecast (in Million), 2010, 2015, 2020, 2025 & 2030
Figure 4:9: India: Breakup of Diabetes Patients* by Urban/Rural Regions, (in %), 2010 & 2030
Figure 4:10: India (Male & Female): Total Number of Diabetes Patients* (in Million), 2005 & 2010
Figure 4:11: India (Male & Female): Total Number of Diabetes Patients* Forecast (in Million), 2010, 2015, 2020, 2025 & 2030
Figure 4:12: India: Breakup of Diabetes Patients by Sex, (in %), 2010 & 2030
Figure 4:13: India: Total Number of Diabetes Patients* by Age Group (20-39), (40-59) & (60-79)
Figure 4:14: India: Total Number of Diabetes Patients* by Age Group (20-39), (40-59) & (60-79)
Figure 4:15: India: Breakup of Diabetes Patients by Age Group, (in %), 2010 & 2030
Figure 4:16: Prevalence of Diabetes across various regions in India
Figure 4:17: India: Total Diabetes Diagnosed & Drug Treated Population*, 2005, 2010 & 2015
Figure 5:1: India: Diabetes Market, (in Million US$), 2005-2009
Figure 5:2: India: Diabetes Market, Share of Non-Insulin Anti-diabetics and Insulin (in %),
Figure 5:3: India: Diabetes Market, (in Million US$), 2010-2015
Figure 5:4: India: Diabetes Market Forecast, Share of Non-Insulin Anti-diabetics and Insulin (in %),
Figure 6:1: India: Non-Insulin Anti-diabetics Sales, (in Million US$), 2005-2009
Figure 6:2: India: Non-Insulin Anti-diabetics Market, Value Market Shares of Key Players (in %),
Figure 6:3: India: Non-Insulin Anti-diabetics Sales Forecast, (in Million US$), 2010-2015
Figure 6:4: India: Non-Insulin Anti-diabetics Market, Value Market Shares of Key Classes (in %),
Figure 6:5: India: Non-Insulin Anti-diabetics Market Forecast, Value Shares of Key Classes (in %), 2015
Figure 6:6: India: Glitazones Anti-diabetic Sales, (in Million US$), 2005-2009
Figure 6:7: India: Glitazone Anti-diabetics Market, Value Market Shares of Key Players (in %),
Figure 6:8: India: Glitazone Anti-diabetics Sales Forecast, (in Million US$), 2010-2015
Figure 6:9: Biguanide Anti-diabetics Sales, (in Million US$), 2005-2009
Figure 6:10: India: Biguanide Anti-diabetics Market, Value Market Shares of Key Players (in %),
Figure 6:11: India: Biguanide Anti-diabetics Sales Forecast, (in Million US$), 2010-2015
Figure 6:12: India: Sulphonylurea Anti-diabetics Sales, (in Million US$), 2005-2009
Figure 6:13: India: Sulphonylurea Anti-diabetics Sales Forecast, (in Million US$), 2010-2015
Figure 6:14: India: Alpha-Glycosidase Inhibitor Anti-diabetics Sales, (in Million US$), 2005-2009
Figure 6:15: India: Alpha-Glycosidase Inhibitor Market, Value Market Shares of Key Players (in %),
Figure 6:16: India: Alpha Glycosidase inhibitor Anti-diabetics Sales Forecast, (in Million US$),
Figure 6:17: India: DPP-IV Inhibitors Sales, (in Million US$), 2008 & 2009
Figure 6:18: India: DPP-IV Inhibitors, Value Market Shares of Key Players (in %), 2008 & 2009
Figure 6:19: India: DPP-IV Inhibitor Anti-diabetics Sales Forecast, (in Million US$), 2010-2015
Figure 6:20: India: Glinides Anti-diabetics Sales, (in Million US$), 2005-2009
Figure 6:21: India: Glinides Anti-diabetics Market, Value Market Shares of Key Players (in %),
Figure 6:22: India: Glinides Anti-diabetics Sales Forecast, (in Million US$), 2010-2015
Figure 6:23: India: Glp-1 Agonist Anti-diabetics Sales, (in 000’ US$), 2008 & 2009
Figure 6:25: India: Glp-1 Agonist Anti-diabetics Sales Forecast, (in Million US$), 2010-2015
Figure 6:26: India: All other Classes Anti-diabetics Sales, (in Million US$), 2005-2009
Figure 6:27: India: All Other Classes Anti-diabetics Market, Value Market Shares of Key Players
Figure 6:28: India: All other Anti-diabetics Classes Sales Forecast, (in Million US$), 2010-2015
Figure 7:1: India: Insulin Sales, (in Million US$), 2005-2009
Figure 7:2: India: Insulin Market, Value Market Shares of Key Molecules (in %),
Figure 7:3: India: Insulin Market, Value Market Shares by Mode of Action (in %), 2009
Figure 7:4: India: Insulin Market, Value Market Shares of Key Players (in %),
Figure 7:5: India: Insulin Sales Forecast, (in Million US$), 2010-2015
Figure 8:1: Average per patient spending on Diabetes Drugs by Major Developed and Emerging Markets, 2010
LIST OF TABLES
Table 2 1: Diagnosis of Diabetes
Table 3 1: Statistics of Top Emerging and Developed Diabetes Markets, 2010 & 2030
Table 3 2: Statistics of Top Emerging and Developed Diabetes Markets, 2009
Table 3 3: Drugs Expected to be launched in the Indian Diabetes Market, 2010-2015
Table 4 1: Prevalence of Type-1 & Type2 Diabetes in India
Table 4 2: India: Total Type-2 Diabetes Diagnosed & Drug Treated Population, 2005, 2010 & 2015
Table 5 1: India: Contribution of Non-Insulin Anti-diabetics & Insulin towards Total Growth,
Table 6 1: India: Non-Insulin Anti-diabetics Market, Sales of Key Players (in 000’ US$),
Table 6 2: India: Non-Insulin Anti-diabetics Market, Sales of Key Classes (in 000’ US$),
Table 6 3: India: Non-Insulin Anti-diabetics Market, Value Shares of Key Classes (in %),
Table 6 4: India: Non-Insulin Anti-diabetics Market Forecasts, Sales of Key Classes (in 000’ US$),
Table 6 5: India: Non-Insulin Anti-diabetics Market Forecasts, Value Shares of Key Classes (in %),
Table 6 6: India: Glitazone Anti-diabetics Market, Sales of Key Players (in 000’ US$),
Table 6 7: India: Sun Pharma’s Glitazone Portfolio Sales (in 000’ US$), 2005-2009
Table 6 8: India: USV’s Glitazone Portfolio Sales (in 000’ US$), 2005-2009
Table 6 9: India: Micro lab’s Glitazone Portfolio Sales (in 000’ US$), 2005-2009
Table 6 10: India: Piralmal’s Glitazone Portfolio Sales (in 000’ US$), 2005-2009
Table 6 11: India: Daichi’s Glitazone Portfolio Sales (in 000’ US$), 2005-2009
Table 6 12: India: Biguanide Anti-diabetics Market, Sales of Key Players (in 000’ US$), 2005-2009
Table 6 13: India: USV’s Biguanide Portfolio Sales (in 000’ US$),
Table 6 14: India: Sun Pharma’s Biguanide Portfolio Sales (in 000’ US$),
Table 6 15: India: Franco Indian’s Biguanide Portfolio Sales (in 000’ US$),
Table 6 16: India: Piralmal’s Biguanide Portfolio Sales (in 000’ US$),
Table 6 17: India: Panacea Biotech’s Biguanide Portfolio Sales (in 000’ US$),
Table 6 18: India: Sulphonylurea Anti-diabetics Market, Sales of Key Players (in 000’ US$),
Table 6 19: India: Sulphonylurea Anti-diabetes, Value Market Shares of Key Players (in %),
Table 6 20: India: Sanofi Aventis Sulphonylurea Anti-diabetics Portfolio Sales (in 000’ US$),
Table 6 21: India: Dr Reddy’s Sulphonylurea Anti-diabetics Portfolio Sales (in 000’ US$),
Table 6 22: India: USV’s Sulphonylurea Anti-diabetics Portfolio Sales (in 000’ US$),
Table 6 23: India: Serviers’s Sulphonylurea Anti-diabetics Portfolio Sales (in 000’ US$),
Table 6 24: India: Piramal’s Sulphonylurea Anti-diabetics Portfolio Sales (in 000’ US$),
Table 6 25: India: Alpha-Glycosidase Inhibitor Market, Sales of Key Players (in 000’ US$),
Table 6 26: India: Bayer’s Alpha-Glycosidase Inhibitor Portfolio Sales (in 000’ US$),
Table 6 27: India: Daiichi’s Alpha-Glycosidase Inhibhitor Portfolio Sales (in 000’ US$),
Table 6 28: India: Sun Pharma’s Alpha-Glycosidase Inhibhitor Portfolio Sales (in 000’ US$),
Table 6 29: India: Glenmark’s Alpha-Glycosidase Inhibhitor Portfolio Sales (in 000’ US$),
Table 6 30: India: Daichi’s Alpha-Glycosidase Inhibhitor Portfolio Sales (in 000’ US$),
Table 6 31: India DPP-IV Inhibitors, Sales of Key Players (in 000’ US$),
Table 6 32: India: MSD’s DPP-IV Inhibitor Portfolio Sales (in 000’ US$), 2008 & 2009
Table 6 33: India: Novartis’s DPP-IV Inhibitor Portfolio Sales (in 000’ US$), 2008 & 2009
Table 6 34: India: USV’s DPP-IV Inhibitor Portfolio Sales (in 000’ US$), 2008 & 2009
Table 6 35: India: Glinides Anti-diabetics Market, Sales of Key Players (in 000’ US$),
Table 6 36: India: Abbot’s Glinides Portfolio Sales (in 000’ US$), 2005-2009
Table 6 37: India: Torrent’s Glinides Portfolio Sales (in 000’ US$), 2005-2009
Table 6 38: India: Glenmark’s Glinides Portfolio Sales (in 000’ US$), 2005-2009
Table 6 39: India: Orchid’s Glinides Portfolio Sales (in 000’ US$), 2005-2009
Table 6 40: India: Glp-1 Agonist Anti-diabetics Market, Sales of Key Players (in 000’ US$),
Table 6 41: India: Lilly’s Glp-1 Agonist Portfolio Sales (in 000’ US$)
Table 6 42: India: All Other Classes Anti-diabetics Market, Sales of Key Players (in 000’ US$),
Table 6 43: India: Piramal’s All other Anti-diabetics Classes Portfolio Sales (in 000’ US$),
Table 6 44: India: Fourt’s All other Anti-diabetics Classes Portfolio Sales (in 000’ US$), 2005-2009
Table 6 45: India: Charak Pharma’s All other Anti-diabetics Classes Portfolio Sales (in 000’ US$),
Table 6 46: India: Intas’s All other Anti-diabetics Classes Portfolio Sales (in 000’ US$), 2005-2009
Table 6 47: India: Himalaya’s All other Anti-diabetics Classes Portfolio Sales (in 000’ US$),
Table 7 1: India: Insulin Value Shares by Molecule (in 000’ US$), 2005-2009
Table 7 2: India: Insulin Value Shares by Molecule (in %), 2005-2009
Table 7 3: India: Insulin Value Sales by Mode of Action (in 000’US$), 2005-2009
Table 7 4: India: Insulin Value Shares by Mode of Action (in %), 2005-2009
Table 7 5: India: Insulin Market, Sales of Key Players (in 000’ US$), 2005-2009
Table 7 6: India: Abott’s/Novo Nordisk’s Insulin Portfolio Sales (in 000’ US$),
Table 7 7: India: Lilly’s Insulin Portfolio Sales (in 000’ US$), 2005-2009
Table 7 8: India: Sanofi Aventis’s Insulin Portfolio Sales (in 000’ US$), 2005-2009
Table 7 9: India: Biocon’s Insulin Portfolio Sales (in 000’ US$), 2005-2009
Table 7 10: India: Wockhardt Insulin Portfolio Sales (in 000’ US$), 2005-2009